Extensive mutational ctDNA profiles reflect High-grade serous cancer tumors and reveal emerging mutations at recurrence

Extensive mutational ctDNA profiles reflect High-grade serous cancer tumors and reveal emerging mutations at recurrence

Objective: Circulating tumor DNA (ctDNA) offers a minimally-invasive alternative to study genomic changes in recurrent malignancies. With a high recurrence rate, the overall survival in high-grade serous ovarian carcinoma (HGSC) has remained low. Our objectives were to determine whether ctDNA from p...

Full description

Bibliographic Details
Main Authors:	Giovanni Marchi, Anna Rajavuori, Mai T.N. Nguyen, Kaisa Huhtinen, Sinikka Oksa, Sakari Hietanen, Sampsa Hautaniemi, Johanna Hynninen, Jaana Oikkonen
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	Translational Oncology
Subjects:	ctDNA High-grade serous ovarian carcinoma Liquid biopsy Targeted sequencing DNA mutations
Online Access:	http://www.sciencedirect.com/science/article/pii/S1936523323002000

Similar Items

Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis
by: Estela Sánchez-Herrero, et al.
Published: (2022-07-01)

How to Obtain a High Quality ctDNA in Lymphoma Patients: Preanalytical Tips and Tricks
by: Estelle Bourbon, et al.
Published: (2021-06-01)

ctDNA Concentration, MIKI67 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC
by: Yao Chen, et al.
Published: (2020-09-01)

Engineering of a DNA/γPNA Hybrid Nanoreporter for ctDNA Mutation Detection via γPNA Urinalysis
by: Zhichu Xiang, et al.
Published: (2024-09-01)

Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)
by: Jason S. Agulnik, et al.
Published: (2022-02-01)

Current status of ctDNA in precision oncology for hepatocellular carcinoma
by: Yan Li, et al.
Published: (2021-04-01)

A comparative study on ctDNA and tumor DNA mutations in lung cancer and benign cases with a high number of CTCs and CTECs
by: Jianzhu Xie, et al.
Published: (2023-12-01)

Why the Therapeutic Impact of RAS Mutation Clearance in Plasma ctDNA Deserves to Be Further Explored in Metastatic Colorectal Cancer
by: Chiara Nicolazzo, et al.
Published: (2019-12-01)

Target Recognition– and HCR Amplification–Induced In Situ Electrochemical Signal Probe Synthesis Strategy for Trace ctDNA Analysis
by: Aiting Cai, et al.
Published: (2022-11-01)

Clinical applications and utility of ctDNA in cervical cancer and its precursor lesions: from screening to predictive biomarker
by: Li Li, et al.
Published: (2023-12-01)

Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapy
by: Xiaohong Han, et al.
Published: (2019-10-01)

Assessments of TP53 and CTNNB1 gene hotspot mutations in circulating tumour DNA of hepatitis B virus-induced hepatocellular carcinoma
by: Sonu Kumar, et al.
Published: (2023-08-01)

Analytical validation of an error-corrected ultra-sensitive ctDNA next-generation sequencing assay
by: Heidi Fettke, et al.
Published: (2020-08-01)

Exploring the Clinical Value of Perioperative ctDNA‐Based Detection of Molecular Residual Disease in Patients With Esophageal Squamous Cell Carcinoma
by: Jimin Li, et al.
Published: (2025-02-01)

Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy
by: Xiaoling Wang, et al.
Published: (2024-01-01)

Liquid Biopsy, ctDNA Diagnosis through NGS
by: Chen Lin, et al.
Published: (2021-08-01)

The utilisation of ctDNA approaches for residual disease detection during neoadjuvant and perioperative immunotherapy in oesophagogastric cancers
by: Ronan J. Kelly, et al.
Published: (2025-02-01)

Basic ctDNA Panel Promises Affordable Clinical Validity in Colon Cancer Patients but Not in Pancreas Cancer Patients
by: Mandy Radefeldt, et al.
Published: (2023-11-01)

The association of blood ctDNA levels to mutations of marker genes in colorectal cancer
by: Fei Bai, et al.
Published: (2023-04-01)

Benchmarking UMI-aware and standard variant callers for low frequency ctDNA variant detection
by: Rugare Maruzani, et al.
Published: (2024-09-01)

Presence of mEGFR ctDNA predicts a poor clinical outcome in lung adenocarcinoma
by: Taehee Kim, et al.
Published: (2019-12-01)

EGFR‐plasma mutations in prognosis for non‐small cell lung cancer treated with EGFR TKIs: A meta‐analysis
by: Thang Thanh Phan, et al.
Published: (2022-08-01)

Clinical utility of ctDNA by amplicon based next generation sequencing in first line non small cell lung cancer patients
by: Valerio Gristina, et al.
Published: (2024-09-01)

Near-Infrared Light Regulation of Capture and Release of ctDNA Platforms Based on the DNA Assembly System
by: Chaihong Gong, et al.
Published: (2022-06-01)

Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature
by: Klempner SJ, et al.
Published: (2017-12-01)

The Potential Use of Dynamics Changes of ctDNA and cfDNA in the Perioperative Period to Predict the Recurrence Risk in Early NSCLC
by: Xiaolong Zhao, et al.
Published: (2021-07-01)

Genome-wide quantification of copy-number aberration impact on gene expression in ovarian high-grade serous carcinoma
by: Sanaz Jamalzadeh, et al.
Published: (2024-02-01)

High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2− postmenopausal breast cancer patients treated with everolimus and exemestane
by: Dinja T. Kruger, et al.
Published: (2020-03-01)

Blood, Toil, and Taxoteres: Biological Determinants of Treatment-Induced ctDNA Dynamics for Interpreting Tumor Response
by: Christopher T. Boniface, et al.
Published: (2022-05-01)

ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA
by: Ariana Huebner, et al.
Published: (2023-04-01)

Detectable ctDNA at the time of treatment cessation of ipilimumab and nivolumab for toxicity predicts disease progression in advanced melanoma patients
by: Lydia Warburton, et al.
Published: (2023-12-01)

Corrigendum: Blood, toil, and taxoteres: Biological determinants of treatment-induced ctDNA dynamics for interpreting tumor response
by: Christopher T. Boniface, et al.
Published: (2023-03-01)

Analysis of solid tumor mutation profiles in liquid biopsy
by: Sai A. Balaji, et al.
Published: (2018-11-01)

Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer
by: Fulong Wang, et al.
Published: (2023-12-01)

Next-Generation Sequencing Analysis of ctDNA for the Detection of Glioma and Metastatic Brain Tumors in Adults
by: Jianfeng Liang, et al.
Published: (2020-08-01)

Harnessing liquid biopsies: Exosomes and ctDNA as minimally invasive biomarkers for precision cancer medicine
by: Oluwaseun Adebayo Bamodu, et al.
Published: (2023-12-01)

Potential predictive value of circulating tumor DNA (ctDNA) mutations for the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer
by: Qiaorui Tan, et al.
Published: (2023-03-01)

ctDNA Detection Based on DNA Clutch Probes and Strand Exchange Mechanism
by: Huan Chang, et al.
Published: (2018-10-01)

A perspective review on the systematic implementation of ctDNA in phase I clinical trial drug development
by: Nolwen Guigal-Stephan, et al.
Published: (2025-03-01)

Acridine Based <i>N</i>-Acylhydrazone Derivatives as Potential Anticancer Agents: Synthesis, Characterization and ctDNA/HSA Spectroscopic Binding Properties
by: Mária Vilková, et al.
Published: (2022-04-01)